Could CBD help curb opioid cravings? new study investigates

NCT ID NCT06206291

Completed Disease control Sponsor: Yasmin Hurd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether cannabidiol (CBD) can reduce craving and anxiety in 76 adults with opioid use disorder who were already on opioid agonist therapy (like methadone). Participants took CBD or a placebo twice daily for 4 weeks, then all took a higher dose of CBD for another 4 weeks. The study measured changes in craving, anxiety, and drug use through urine tests and self-reports.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cannabidiol (CBD)
What this could lead to: If it works, CBD could become a safe, non-addictive add-on treatment to help people with opioid use disorder manage cravings and stay in recovery.
What could go wrong: This is a small, early-phase trial (76 people) with no placebo comparison for the full 8 weeks. Results may not apply to everyone, and CBD's effects on opioid craving are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.